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Acute respiratory distress syndrome (ARDS) is a severe respiratory failure caused by acute lung
inﬂammation. Recently, the receptor for advanced glycation end-products (RAGE) has attracted attention
in the lung inﬂammatory response. However, the function of soluble form of RAGE (sRAGE), which is
composed of an extracellular domain of RAGE, in ARDS remains elusive. Therefore, we investigated the
dynamics of pulmonary sRAGE and the effects of exogenous recombinant human sRAGE (rsRAGE) under
intratracheal lipopolysaccharide (LPS)-induced lung inﬂammation. Our result revealed that RAGE was
highly expressed on the alveolar type I epithelial cells in the healthy rat lung including sRAGE isoform
sized 45 kDa. Under LPS-induced injured lung, the release of sRAGE into the alveolar space was increased,
whereas the expression of RAGE was decreased with alveolar disruption. Treatment of the injured lung
with rsRAGE signiﬁcantly suppressed the lung edema, the neutrophils inﬁltration, the release of high
mobility group box-1 (HMGB1), and the expressions of TNF-a, IL-1b and iNOS. These results suggest that
the alveolar release of sRAGE may play a protective role against HMGB1 as well as exogenous pathogen-
associated molecular patterns. Supplementary therapy with sRAGE may be an effective therapeutic
strategy for ARDS.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Acute respiratory distress syndrome (ARDS) is characterized by
the rapid onset of life-threatening respiratory failure as a conse-
quence of severe acute inﬂammatory diseases (1). ARDS are
induced by a diverse range of risk factors, including direct lung
injury (e.g., bacterial or viral pneumonia, lung contusion, or toxic
inhalation) and indirect lung injury induced by systemic insults
(e.g., sepsis, burn, or pancreatitis) (2). The inﬁltrated neutrophilsishibori).
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d/4.0/).and macrophages exacerbate the lung inﬂammation by releasing
pro-inﬂammatory mediators and reactive oxygen species, acti-
vating proteolytic enzymes, and so on (3). The pathophysiology of
severe pulmonary inﬂammation is characterized by diffuse alveolar
damage, alveolar capillary leakage, and protein rich pulmonary
edemawith alveolar epithelial and endothelial injury (3,4). Despite
our current knowledge of the pathophysiology of ARDS, as
described above, and the various therapeutic strategies that have
been examined, there remains no established therapy for clinical
use (4).
In 1992, an advanced glycation end-products (AGEs)-binding
protein was initially puriﬁed and identiﬁed from the bovine lung
and designated a receptor for AGEs (RAGE) (5). RAGE is a singlenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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Fig. 1. Tissue distribution of RAGE isoforms in normal rat tissues. (A) Tissue ho-
mogenates were prepared from normal rat organs including lung tissue and subjected
to immunoblot analysis with anti-rsRAGE antibody. RAGE isoforms in the indicated
organs were detected by using a DAB reaction (A) or ECL system (B). Puriﬁed rsRAGE
with 6 tandem histidine-tags was used as a positive control in (A). The left lane in (B)
shows the result when loading a whole fraction of the lung homogenate, including the
insoluble components of the plasma membrane, and the middle lane the result for a
supernatant fraction including only soluble components. The right lane in (B) shows
the result when loading a pellet fraction including the insoluble fraction.
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ligand-binding domain, a transmembrane domain, and a short
cytoplasmic domainwhich is essential for signal transduction (6,7).
Moreover, RAGE has a soluble form protein (soluble RAGE (sRAGE))
composed of an extracellular ligand-binding domain without the
transmembrane and cytoplasmic domains (7).
RAGE can bind to not only AGEs but also endogenous damage-
associated molecular patterns (DAMPs) such as high mobility
group box-1 (HMGB1), several members of the S100 protein family,
amyloid b peptide, b2-integrin and pathogen-associated molecular
patterns (PAMPs) such as lipopolysaccharide (LPS) (8,9). In addi-
tion, RAGE is considered to be a typical pattern-recognition re-
ceptors (PRRs), with potential similarity to members of the toll-like
receptors (TLRs) family in the innate immune system as a ﬁrst line
of host defense (10,11).
It is particularly worth noting that RAGE is constitutively and
predominantly expressed in the lung at high levels, whereas it is
expressed at low levels in almost all cells under normal conditions
(12). Therefore, it is considered that RAGE may have an important
function in lung homeostasis (13).
Recently, it has been reported that sRAGE levels are increased in
the plasma and bronchoalveolar lavage ﬂuid (BALF) of rodent
models and human patients with ARDS (14). In particular, sRAGE
release into BALF may be a good biomarker to estimate the severity
of lung injury (15). However, the physiological function of sRAGE
remains elusive. In vivo experiments using a lung injurymodel have
been inconsistent and controversial in terms of the protective ef-
fects of sRAGE (16,17).
In the present study, we investigated the in vivo effects of pu-
riﬁed recombinant human sRAGE (rsRAGE) administered intra-
tracheally to a rat model of LPS-induced lung injury, and the
underlying mechanism of its anti-inﬂammatory actions in the
environment of the injured lung.
2. Material and methods
2.1. Animals and LPS-induced lung injury model
All animal protocols were approved and conducted according to
the recommendations of the Okayama University Animal Care and
Use Committee. Male Wistar rats at 8e11 weeks old and weighing
300 ± 50 g were purchased from Japan SLC (Shizuoka, Japan) or
Japan Charles River (Yokohama, Japan). The LPS-induced lung
injury model was established according to the method described
previously (14). Under anesthesia, LPS (Escherichia coli O111:B4)
(SigmaeAldrich, St. Louis, MO, USA) at 5 mg/kg as a solution of
5 mg/mL or an equivalent volume of saline as a vehicle control was
administered intratracheally through a catheter. Rats were sacri-
ﬁced to obtain tissue samples at 0.5, 6, 24, and 48 h after LPS-
induced lung injury. To evaluate the in vivo effects of rsRAGE for
LPS-induced lung injury, rats were also intratracheally treated with
rsRAGE at 1mg/kg as a solution of 1 mg/mL or an equivalent dose of
human serum albumin (HSA) (SigmaeAldrich) as a protein control
after 1 h of LPS-induced lung injury.
2.2. Puriﬁcation of recombinant human soluble RAGE
rsRAGE was produced by the method as previously described
(18).
2.3. BALF analysis
Twenty-four hours after LPS administration, BALF was collected
by irrigating the lung 3 times with 5 mL of cold saline for analysis.2.4. Immunoblot analysis
Immunoblot analysis was performed to detect the RAGE by
using the antibody against rsRAGE, which was house-made and
raised in a rabbit, and detected both the soluble isoform and
transmembrane isoform.2.5. Immunohistochemistry
Immunohistochemical staining was performed as previously
described (19) using antibody against rsRAGE, Podoplanin (Acris,
San Diego, CA, USA), P180 LBP (Abcam, Cambridge, UK), CD68
(Abcam), Myeloperoxidase (MPO) (Abcam) and HMGB1 (Abcam
and R&D, Minneapolis, MN, USA).2.6. Measurement of HMGB1 by ELISA
A sensitive and speciﬁc anti-HMGB1 monoclonal antibody-
based sandwich enzyme-linked immunosorbent assay (ELISA)
was established. The capture and detection antibodies were pro-
duced by our group as described previously (19).2.7. Naphthol AS-D chloroacetate esterase stain
Naphthol AS-D chloroacetate esterase stain was performed to
count the inﬁltrating active neutrophils as previously described
(20).
Fig. 2. Immunohistochemical localization of RAGE in the normal rat lung. (AeB) Lung sections were immunostained with anti-rsRAGE antibody followed by initiation of a DAB
reaction. The black, green and red arrowheads indicate a RAGE-positive AECI, a RAGE-negative AECII and a RAGE-negative alveolar macrophage, respectively. (C) Double-
immunoﬂuorescent staining of lung tissue with anti-rsRAGE (Alexa Fluor 488) and with anti-podoplanin (Alexa Fluor 555) antibodies. The right panel shows a high magniﬁca-
tion of the region in the white square in the left panel. (D) Double-immunoﬂuorescent staining of lung tissue with anti-rsRAGE (Alexa Fluor 488) and anti-P180 LBP (Alexa Fluor
555) antibodies. (E) Double-immunoﬂuorescent staining of lung tissue with anti-rsRAGE (Alexa Fluor 488) and with anti-CD68 (Alexa Fluor 555) antibodies. The sections were
counterstained with hematoxylin (AeB) or DAPI (CeE). The scale bars indicate 20 mm (A, C-E) or 10 mm (magniﬁcation panel in (C)).
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Lung edema was assessed by measuring the tissue wet/dry
weight ratio as previously described (21).
2.9. Real-time quantitative PCR analysis
Total RNAwas extracted from the lung tissue by using an RNeasy
kit (QIAGEN, Hilden, Germany), and then total RNA was reverse-
transcribed by using a Takara PrimeScript RT reagent kit (Takara,Siga, Japan). Real-time quantitative PCR analysis was performed
described previously (19). The ampliﬁcation of each PCR product
was conﬁrmed by analyzing a melting curve of the PCR products
(22).
2.10. Statistical analysis
Statistical comparisons of experiments were performed using a
one-way ANOVA followed by the post hoc Dunnett's test. The sta-
tistical comparisons of BALF analysis were performed using a
Fig. 3. LPS-induced changes in RAGE immunoreactivities in the injured lung. Lung sections were prepared from the intact rats in the 9 panels at left or from rats 48 h after
intratracheal LPS administration in the 9 panels at right. Double-immunoﬂuorescent staining for RAGE (Alexa Fluor 488) and podoplanin (Alexa Fluor 555), P180 LBP (Alexa Fluor
555), or CD68 (Alexa Fluor 555) were performed as in Fig. 2. The scale bars indicate 20 mm.
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SE. P-values less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Distribution and localization of RAGE expression in normal rats
Several major organs were examined by immunoblot analysis,
and the RAGE protein levels were highest in the lungs (Fig. 1A).
While three major bands corresponding to molecular weights of
approximately 45, 51 and 54 kDa were detected in the whole and
insoluble pellet fraction of the lung homogenate, the supernatant
fraction of the lung homogenate showed only a single band with a
molecular weight of 45 kDa (Fig. 1B).
To conﬁrm that RAGE expression was localized in the lung,
immunohistochemical staining was performed. Anti-rsRAGE
immunoreactivity was prominent along with the alveolar epithe-
lium cell layer in the histological structure (Fig. 2A), but was not
observed in AECII and alveolar macrophages on the basis of the
morphological features (Fig. 2B). We also conﬁrmed that the
expression of RAGE was colocalized quite clearly to the
podoplanin-positive AECI (Fig. 2C), but not observed in the P180
LBP-positive AECII (Fig. 2D) or CD68-positive alveolar macro-
phages (Fig. 2E).
3.2. Alteration of RAGE expression under LPS-induced lung injury
LPS has a toxic component, endotoxin, that is derived from a
component of the Gram-negative bacterial cell wall and is the
leading cause of ARDS. We used the intratracheal LPS-induced lung
injury rat model to examine the role of RAGE under a pathological
condition. Forty-eight hours after LPS administration, the alveolar
structure was dramatically altered and showed inﬂammatory fea-
tures, leading to a marked decrease in the podoplanin-immunoreactivities (Fig. 3A), an increase in the P180 LBP-positive
AECII (Fig. 3B), and a severe inﬁltration of the CD68-positive alve-
olarmacrophages into the pulmonary alveolus (Fig. 3C). In addition,
the ﬂuorescence intensity for RAGE was also remarkably decreased
in the injured lung along with the decreased podoplanin-
immunoreactivities (Fig. 3A).
Following the immunohistological analysis, we performed
quantitative determination of the alteration of RAGE expression in
the injured lung. Immunoblot analysis showed that administration
of LPS to the lung resulted in a signiﬁcant decrease of RAGE iso-
forms with molecular weights of 45, 51 and 54 kDa in a time-
dependent manner (Fig. 4AeD). The 54-kDa RAGE isoform was
almost undetectable at 0.5 h after LPS administration. RAGE levels
in the saline-treated group were not signiﬁcantly different from
those in the intact rat group. Essentially identical results were also
observed following intravenous LPS administration to the rat tail
vein (date not shown). Real-time quantitative PCR analysis revealed
that the pulmonary expression level of RAGE mRNA was signiﬁ-
cantly decreased by LPS administration in a time-dependent
manner (Fig. 4E), which was consistent with the results of the
immunoblot analysis.3.3. sRAGE release into the alveolar space under LPS-induced lung
injury
To assess the inﬂammation grade of the LPS-induced lung injury
model, BALF samples were prepared from the lungs at 24 h after LPS
administration. Immunoblot analysis did not detect any isoforms of
RAGE from the control BALF. However, the BALF derived from the
injured lung showed the clear existence of the 45-kDa RAGE iso-
form, which was considered to be a soluble isoform (Fig. 5A). The
release into BALF of HMGB1, which is an initial inﬂammatory
mediator, was signiﬁcantly increased by LPS stimulus (Fig. 5B).
Fig. 4. Change in RAGE isoforms in lung tissue after intratracheal LPS administration. Whole lung homogenate was prepared from the intratracheal LPS- or saline-administered
rats at the indicated times and subjected to immunoblot analysis with anti-rsRAGE antibody. (A) The left-most lane represents the intact rat sample as a control. b-actin was used as
a loading control. (BeD) The 45-, 51-, and 54-kDa isoforms of RAGE were quantiﬁed, respectively. (E) Total RNAwas isolated from lung tissue under the same conditions as in (A) and
subjected to real-time quantitative PCR for analysis of the expression of RAGE mRNA. GAPDH was used as a housekeeping gene. Values represent the means ± SE (n ¼ 4e5 rats for
(AeD), n ¼ 7e8 rats for (E)). *P < 0.05, **P < 0.01 compared with the saline-group at each of the indicated time points. yP < 0.05, yyP < 0.01 compared with the intact rat group in
(BeD). ##P < 0.01 compared with the control saline-group at 0.5 h in (E).
Y. Izushi et al. / Journal of Pharmacological Sciences 130 (2016) 226e234230Similarly, both the total cell number and protein contents in BALF
were signiﬁcantly increased by LPS administration (Fig. 5CeD).
3.4. Anti-inﬂammatory effects of rsRAGE treatment on the LPS-
induced lung injury
Finally, we evaluated whether the inﬂammatory condition of
LPS-induced lung injury was ameliorated by therapeutic treatment
with intratracheally-injected puriﬁed rsRAGE.Consistent with the LPS-induced inﬂammatory responses
shown in Fig. 3 and Fig. 5, the number of naphthol AS-D chlor-
oacetate esterase-positive neutrophils in lung tissue and the lung
wet/dry weight ratio were signiﬁcantly increased at 24 h after LPS
administration. The rsRAGE treatment of the injured lung signiﬁ-
cantly decreased these pathological parameters (Fig. 6AeB and
Fig. 7A). In immunohistochemical staining, the anti-inﬂammatory
effects of rsRAGE on the injured lung were also apparent based
on the reduction in excessive inﬁltrating inﬂammatory cells, and
Fig. 5. Release of the sRAGE isoform and HMGB1 into the BALF after intratracheal administration of LPS. The BALF was collected from the intratracheal LPS- or saline-
administered rats at 24 h. (A) Immunoblot analysis with anti-rsRAGE antibody was performed and the results were quantiﬁed. The background area in each lane was used to
adjust the quantiﬁcation. (B) The HMGB1 concentration in the BALF was measured by ELISA. (C) Total cells in BALF were counted. (D) The protein concentration was measured.
Values represent the means ± SE (n ¼ 3). *P < 0.05, **P < 0.01 compared with the control saline-group. N.D.: not detectable.
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arrows in Fig. 6E) in AECI and macrophages (Fig. 6CeE). However,
the inﬁltrated neutrophils did not translocate the nuclear HMGB1
24 h after LPS stimulation. Furthermore, under the same conditions
as in Fig. 6, real-time quantitative PCR analysis showed that the
gene expressions for inﬂammatory cytokines such as IL-1b, TNF-a
and iNOS were signiﬁcantly increased in the injured lung
(Fig. 7BeD). Treatment of the injured lung with rsRAGE signiﬁ-
cantly suppressed the increased expression of these genes
(Fig. 7BeD).4. Discussion
We have shown that intratracheal treatment with puriﬁed
rsRAGE ameliorated the inﬂammatory conditions in an LPS-
induced model of lung injury. The pathological alteration of
sRAGE expression revealed in the present study is potentially
important for understanding the overall inﬂammatory responses in
the pulmonary alveolus, which in turn is crucial for understanding
the pathogenesis of ARDS. The contribution of rsRAGE to the anti-
inﬂammatory effects in the injured lung was revealed by the
attenuation of pulmonary edema, the decreased inﬁltration of in-
ﬂammatory cells and the suppressed expression of inﬂammatory
cytokines. The treatment of rsRAGE appeared to play an important
role in protecting the lung against LPS-induced damage.In the normal rat lung tissue, RAGE was predominantly
expressed in three main isoforms detected as approximately 45, 51
and 54 kDa bands (Fig. 1B). The 45-kDa isoform of RAGE was pre-
sent in the supernatant fraction of lung homogenate, which is
considered a soluble isoform lacking a transmembrane domain.
These results are consistent with the ﬁndings previously described
(14).
RAGE protein was predominantly localized to the plasma
membrane of AECI in the pulmonary alveolus under normal con-
ditions (Fig. 2). The AECI linings constitute more than 98% of the
internal surface area in the rodent pulmonary alveolus, which is
essential to pulmonary homeostasis through the integrity of the
alveolar epithelial barrier, gas exchange and alveolar ﬂuid clearance
(23).
On the other hand, AECI is constantly exposed to invasions of a
wide range of infectious pathogens and/or foreign antigens from
the external environment and host-derived danger signals. Under
AECI injury, podoplanin is suggested to be a sensitive marker of
ARDS based on the ﬁndings that podoplanin and its related ho-
mologs were released into BALF in bleomycin-induced or Pseudo-
monas aeruginosa-induced lung injury (24,25). Thus, the apparent
decrease in podoplanin immunoreactivities in LPS-induced lung
injury strongly suggests damage to the AECI in our rat model
(Fig. 3). It is known that AECII proliferate, migrate and transform
into AECI in ARDS (25,26). Therefore, the considerable increase in
the number of AECII in LPS-induced lung injury observed in the
Fig. 6. Effects of rsRAGE treatment on the number of neutrophils and the HMGB1 localization in LPS-induced injured lung. Lung tissues were prepared after intratracheal LPS
administration with rsRAGE (LPS þ rsRAGE) or HSA (LPS þ HSA). The Sham group (Sal þ Sal) was administered saline alone. (A) Naphthol AS-D chloroacetate esterase staining was
performed for the identiﬁcation of neutrophils. The inﬁltrated neutrophils in the lung are represented by Naphthol AS-D-positive cells as the deep dye staining. The sections were
counterstained with hematoxylin. (B) Cell density of the activated neutrophils was quantiﬁed by counting Naphthol AS-D-positive cells. (CeE) Double-immunoﬂuorescent staining
of lung tissue with anti-HMGB1 (Alexa Fluor 555) and anti-Podoplanin (Alexa Fluor 488), anti-MPO (Alexa Fluor 488), or anti-CD68 (Alexa Fluor 488) antibodies were performed on
three groups. The white squares and their magniﬁed pictures show the typical patterns of HMGB1 distribution in each group. The most right panel in each group represent the spot-
checked distribution of HMGB1 by Z-stack analysis in CD68-positive alveolar macrophage in the adjacent picture (white square). White arrows in (C) and (E) indicate the intra-
nuclear localization of HMGB1. White arrowheads in (D) indicate the extranuclear localization of HMGB1. The sections were counterstained with DAPI. The scale bars indicate
20 mm (A, C-E) or 5 mm (3D confocal analysis in (CeE)). Values represent the means ± SE (n ¼ 4e6 rats). **P < 0.01 compared with the LPS þ HSA group. yyP < 0.01 compared with the
Sal þ Sal group.
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injured. Taken together, our observations suggest that the AECI
suffered pathological alteration or lethal damage leading to alveolar
disruption. Such a feature of AECI injury could result in the respi-
ratory failure with high mortality seen in ARDS (1).
Interestingly, it has been reported that AECI may be a more
important and active player than AECII in host defense through theinnate immune response in the lungs (27). RAGE has the potential
to induce inﬂammatory responses by directly binding with LPS (9).
Therefore, it might be possible that RAGE on AECI constitute a
sensory alarm system in the pulmonary innate immune response
against PAMPs/DAMPs.
In the presence of LPS-induced lung injury, both the expression
and production of RAGE were decreased with striking damage to
Fig. 7. Effects of rsRAGE treatment on pulmonary edema and the expression of inﬂammatory cytokines in the LPS-induced injured lung. Lung tissues were prepared from the
intratracheal LPS-administered rats treated with rsRAGE (LPS þ rsRAGE) or HSA (LPS þ HSA). The Sham group (Sal þ Sal) was administered saline alone. (A) The lung wet/dry weight
ratio was determined in each group. (BeD) Total RNAwas isolated from each group of lungs and subjected to real-time quantitative PCR analysis for determination of the expression
of IL-1b (B), TNF-a (C) and iNOS (D). GAPDH was used as a housekeeping gene. Values represent the means ± SE (n ¼ 4e6 rats for (A), n ¼ 6e8 rats for (BeD)).*P < 0.05, **P < 0.01
compared with the LPS þ HSA group. yyP < 0.01 compared with the Sal þ Sal group.
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remarkable decrease in RAGE isoforms in lung tissue under the
intravenous LPS-induced lung injury in rats (date not shown). The
decrease in RAGE protein in the injured lung has also been observed
in other animal models of lung injury, such as E. coli-induced lung
injury, asbestos-induced idiopathic pulmonary ﬁbrosis, and
bleomycin-induced lung ﬁbrosis (17,28,29). These results suggest
that RAGE expression in lung tissue is decreased in AECI under
strong inﬂammatory conditions.
However, several have also reported that RAGE was increased in
the lung tissue of experimental models of lung injury induced by
cigarette smoke or hyperoxia (30,31). This discrepancy may be due
to differences in the degree, frequency or persistence of inﬂam-
matory stimulation compared to our injury model. Thus, mild and
low levels of inﬂammatory stimuli might induce an increase of
RAGE expression in response to various PAMPs/DAMPs in a sensi-
tivemanner duringmild lung injury. As a result, the increased RAGE
expression may enhance an innate immune response in lung tissue
as a host defense mechanism. However, when the stimulus levels
by invading PAMPs/DAMPs exceed the homeostatic levels, lethal
alternation of AECI may occur, leading to severe damage and cell
death of AECI. Under such conditions, RAGE expression would
decrease, attenuating the subsequent inﬂammatory response. The
alteration of RAGE expression under severe lung injury may
contribute to a decrease in excessive inﬂammatory responses
through the reduced RAGE signaling in AECI. Thus, RAGE expres-
sion on AECI may be regulated by the severity of lung injury.
In the alveolar space, sRAGE was dramatically increased by LPS
stimulation in BALF, in association with protein leakage and theinﬁltration of neutrophils and macrophages (Fig. 5), whereas both
the mRNA expression and protein production of RAGE were
signiﬁcantly decreased in the injured lungs (Fig. 4). In experimental
models of ARDS, we also consider that sRAGE is produced by pro-
teolytic cleavage of membrane-bound RAGE isoforms by extracel-
lular proteases (32).
Looking at the sRAGE ﬁndings more closely, it can be seen that,
among the three major RAGE isoforms, sRAGE had the highest in-
tensity in the whole homogenate and in the supernatant fraction of
the intact rat lungs (Figs. 1B and 4A), whereas sRAGE could not be
detected in BALF in the sham group (Fig. 5A). These results suggest
that a large amount of 45 kDa sRAGE isoform might be constantly
present in a storage pool in the normal rat lung that may be rapidly
released into the alveolar space under the early stage of lung injury.
Although further investigation is necessary, sRAGE would have a
very important physiological function in the lung tissue.
To conﬁrm the conjectured function of sRAGE in lung injury, we
evaluated the effect of rsRAGE on the inﬂammatory responses
under LPS-induced lung injury. Many pathological responses in the
injured lung were signiﬁcantly improved by rsRAGE treatment,
including the excessive pulmonary inﬁltration of inﬂammatory
cells, the increase of lung edema and the expression of inﬂamma-
tory cytokines (Figs. 6 and 7). The anti-inﬂammatory effects of
rsRAGE in the injured lung were also conﬁrmed by the suppression
of HMGB1 translocation in AECI and alveolar macrophages, as
shown by a histological study (Fig. 6CeE). However, inﬁltrated
neutrophils appeared not to be the source of released HMGB1
(Fig. 6CeE). Thus, HMGB1 is probably released from activated
macrophages and AECI in the LPS-induced lung injury in the
Y. Izushi et al. / Journal of Pharmacological Sciences 130 (2016) 226e234234present study. Not only RAGE but also TLR4 has been recognized as
HMGB1 receptor (10). Since up-regulation of TLR4 was reported on
the same LPS-induced lung injury model in rats (33), TLR4 also
might be involved in the action of extracellular HMGB1. Therefore,
we consider that one of the anti-inﬂammatory effects of rsRAGE in
the injured lung is due to a neutralizing effect of sRAGE by binding
to not only LPS but also the released HMGB1 fromdamaged alveolar
epithelial cells and activated alveolar macrophages for inhibition of
these ligands binding to RAGE, TLR4, or other cell surface receptors.
Taken together, our present study suggests that sRAGE treatment
has the potential to ameliorate lung injury in conditions such as
ARDS.
Several reports have supported that sRAGE acts as a decoy re-
ceptor (9,16,34). However, another study reported that sRAGE did
not function as a decoy (17). Although little is known about this
discrepancy, our results have provided considerable evidence for
the anti-inﬂammatory function of sRAGE.
In conclusion, our present study suggests that the expression of
RAGE in AECI plays a role for lung inﬂammation. The release of
soluble RAGE from AECI has the potential to attenuate the excessive
inﬂammatory response in ARDS. Although further investigation is
necessary, this study supports the notion that RAGE would be a
promising candidate for a molecular target in the treatment of
ARDS.
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